Brief: Cardiff Oncology Announces Plans For A Randomized Trial In Metastatic Colorectal Cancer (mCRC), Durability Of Responses In Ongoing Phase 1b/2 Trial In mCRC And Additional Business Updates
12/09/2022 22:33
Sept 12 (Reuters) - Cardiff Oncology Inc CRDF.O :
* CARDIFF ONCOLOGY ANNOUNCES PLANS FOR A RANDOMIZED TRIAL IN
METASTATIC COLORECTAL CANCER (MCRC), DURABILITY OF RESPONSES IN
ONGOING PHASE 1B/2 TRIAL IN MCRC AND ADDITIONAL BUSINESS UPDATES
* CARDIFF ONCOLOGY INC - BASED ON ITS CURRENT EXPECTATIONS
AND
PROJECTIONS, COMPANY'S CURRENT CASH RESOURCES ARE SUFFICIENT TO
FUND OPERATIONS INTO 2025
* CARDIFF ONCOLOGY INC - RANDOMIZED PHASE 2 ONVANSERTIB
TRIAL
TOPLINE DATA EXPECTED IN 2H 2024
Source text for Eikon: ID:nPn2kFp9la
Further company coverage: CRDF.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cardiff Oncology
See all newsBrief: Cardiff Oncology Receives FDA Orphan Drug Designation For Onvansertib In Chronic Myelomonocytic Leukemia
Corrected: Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Cardiff Oncology Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Cintas, Veradermics
Cardiff Oncology sinks on direct equity offering